Significantly decreased risk factors for HCC mortality were as follows: interferon or nucleoside analog used (HR: 0.7620, p = 0.0016), statin or fibrate used (HR: 0.5710, p = 0.0029), and albumin (HR: 0.7410, p = 0.0001). This evidence concerns the gene ALB and hepatocellular carcinoma.